• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    HUTCHMED to Announce 2024 Half-Year Financial Results

    6/26/24 4:30:00 AM ET
    $HCM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $HCM alert in real time by email

    HONG KONG and SHANGHAI and FLORHAM PARK, N.J., June 26, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM: HCM; SEHK:13) will be announcing its interim results for the six months ended June 30, 2024 on Wednesday, July 31, 2024 at 7:00 am Eastern Daylight Time (EDT) / 12:00 noon British Summer Time (BST) / 7:00 pm Hong Kong Time (HKT).

    Analysts and investors are invited to join a conference call and audio webcast presentation with Q&A, conducted by HUTCHMED management.

    The English conference call and audio webcast will be held on Wednesday, July 31, 2024, at 8:00 am EDT (1:00 pm BST / 8:00 pm HKT). The Chinese (Putonghua) webcast will be held at 8:30 am HKT / 1:30 am BST on Thursday, August 1, 2024 (8:30 pm EDT on Wednesday, July 31, 2024). Both webcasts will be available live via the company website at www.hutch-med.com/event/. The presentation will be available for downloading before the conference call begins. Details of the conference call dial-in will be provided in the financial results announcement and on the company website. A replay will also be available on the website shortly after the event.

    About HUTCHMED

    HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. It has approximately 5,000 personnel across all its companies, at the center of which is a team of about 1,800 in oncology/immunology. Since inception it has focused on bringing cancer drug candidates from in-house discovery to patients around the world, with its first three oncology drugs marketed in China, the first of which is also marketed in the U.S. For more information, please visit: www.hutch-med.com or follow us on LinkedIn.

    CONTACTS

    Investor Enquiries+852 2121 8200 / [email protected]
      
    Media Enquiries 
    Ben Atwell / Alex Shaw, FTI Consulting+44 20 3727 1030 / +44 7771 913 902 (Mobile) / +44 7779 545 055 (Mobile) / [email protected]
    Zhou Yi, Brunswick+852 9783 6894 (Mobile) / [email protected]
      
    Nominated Advisor 
    Atholl Tweedie / Freddy Crossley / Rupert Dearden, Panmure Gordon+44 (20) 7886 2500


    Primary Logo

    Get the next $HCM alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $HCM

    DatePrice TargetRatingAnalyst
    5/13/2025Buy → Hold
    HSBC Securities
    11/24/2023Hold → Buy
    Deutsche Bank
    5/4/2022Buy → Hold
    Deutsche Bank
    9/22/2021$46.00Buy → Neutral
    Goldman
    8/3/2021$52.00Buy
    Jefferies
    More analyst ratings

    $HCM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • HUTCHMED to Announce 2025 Half-Year Financial Results

      HONG KONG and SHANGHAI and FLORHAM PARK, N.J., July 03, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM: HCM; HKEX:13) will announce its interim results for the six months ended June 30, 2025 on Thursday, August 7, 2025 at 7:00 am Eastern Daylight Time (EDT) / 12:00 noon British Summer Time (BST) / 7:00 pm Hong Kong Time (HKT). HUTCHMED management will host two webcast presentations for analysts and investors to discuss the interim results, followed by Q&A sessions. The English webcast will be held on Thursday, August 7, 2025, at 8:00 am EDT (1:00 pm BST / 8:00 pm HKT). The Chinese (Putonghua) webcast will be held at 8:30 am HKT / 1:30 am BST on Friday

      7/3/25 4:30:00 AM ET
      $HCM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HUTCHMED Announces China Approval for ORPATHYS® in Combination with TAGRISSO® for the Treatment of Lung Cancer Patients with MET Amplification After Progression on First-Line EGFR Inhibitor Therapy

      — Approval based on Phase III SACHI Trial results which showed a 66% reduced risk of progression or death as compared to platinum-based chemotherapy — — The only all-oral combination treatment option for these patients — — Consistent benefit regardless of first-line EGFR inhibitor therapy — HONG KONG, SHANGHAI and FLORHAM PARK, N.J., June 30, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:​HCM; HKEX:​13) today announces that the New Drug Application ("NDA") for the combination of ORPATHYS® (savolitinib) and TAGRISSO® (osimertinib) has been granted approval by the China National Medical Products Administration ("NMPA") for the treatment of patients with loca

      6/30/25 4:30:00 AM ET
      $HCM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Renal Cell Carcinoma

      HONG KONG and SHANGHAI and FLORHAM PARK, N.J., June 05, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:​HCM; HKEX:​13) and Innovent Biologics, Inc. ("Innovent") (HKEX: 01801) today jointly announce that the New Drug Application ("NDA") for the combination of fruquintinib and sintilimab for the treatment of patients with locally advanced or metastatic renal cell carcinoma who have failed prior treatment with one tyrosine kinase inhibitor ("TKI") has been accepted for review by the China National Medical Products Administration ("NMPA"). The NDA is supported by data from FRUSICA-2, a randomized, open-label, active-controlled registration study evaluating the effi

      6/4/25 7:45:00 PM ET
      $HCM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HCM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • HUTCHMED downgraded by HSBC Securities

      HSBC Securities downgraded HUTCHMED from Buy to Hold

      5/13/25 3:20:36 PM ET
      $HCM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HUTCHMED upgraded by Deutsche Bank

      Deutsche Bank upgraded HUTCHMED from Hold to Buy

      11/24/23 7:13:23 AM ET
      $HCM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HUTCHMED downgraded by Deutsche Bank

      Deutsche Bank downgraded HUTCHMED from Buy to Hold

      5/4/22 3:18:20 PM ET
      $HCM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HCM
    SEC Filings

    See more
    • SEC Form 6-K filed by HUTCHMED (China) Limited

      6-K - HUTCHMED (China) Ltd (0001648257) (Filer)

      7/3/25 6:10:55 AM ET
      $HCM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by HUTCHMED (China) Limited

      6-K - HUTCHMED (China) Ltd (0001648257) (Filer)

      7/2/25 6:07:02 AM ET
      $HCM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by HUTCHMED (China) Limited

      6-K - HUTCHMED (China) Ltd (0001648257) (Filer)

      6/30/25 6:36:15 AM ET
      $HCM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HCM
    Leadership Updates

    Live Leadership Updates

    See more
    • HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee

      HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 05, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED" or the "Company") (Nasdaq/AIM:​HCM, HKEX:​13) today announces that Mr Wong Tak Wai (Mr Alvin Wong) is appointed as an Independent Non-executive Director and a member of the Audit Committee of the Company with effect from March 6, 2025. Mr Wong has over 35 years of extensive experience in accounting, auditing and corporate finance. He has acted in a pivotal role in assisting companies with their stock exchange listings and has been instrumental in completing numerous mergers and acquisitions. After a distinguished career spanning more than three decades, Mr Wong retired as

      3/5/25 5:00:00 AM ET
      $HCM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee

      HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Nov. 20, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED" or the "Company") (Nasdaq/AIM:HCM, HKEX:13) today announces that Dr Chaohong Hu (Dr Mary Hu) is appointed as an Independent Non-executive Director and a member of the Technical Committee of the Company with effect from November 21, 2024. Dr Hu has over 20 years of experience in the development of therapeutic antibodies, antibody-drug conjugates, and vaccines. Throughout her career, she has demonstrated strong leadership and innovative capabilities, leading various research and development initiatives. Dr Hu's expertise spans from early-stage discovery to clinical developme

      11/20/24 4:30:00 AM ET
      $HCM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HUTCHMED announces retirement of Chairman, appointment of new Chairman and change of members of board committees

      HONG KONG and SHANGHAI and FLORHAM PARK, N.J., May 17, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED" or the "Company") (Nasdaq/AIM:​HCM, HKEX:​13) today announces:- (a) the retirement of Mr Simon To from the position as Chairman and Executive Director, after 23 years with the Company; and (b) the appointment of Dr Dan Eldar as the new Chairman. Dr Eldar has been a Non-executive Director of the Company since 2016. He has more than 30 years of experience as a senior executive, leading global operations in biotechnology, healthcare, telecommunications and water. He is an executive director of Hutchison Water Israel E.P.C Ltd, an associate of CK Hutchison group, which

      5/17/24 10:00:00 AM ET
      $HCM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HCM
    Financials

    Live finance-specific insights

    See more
    • HUTCHMED to Announce 2024 Final Results

      HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Feb. 19, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM: HCM; SEHK:13) will be announcing its final results for the year ended December 31, 2024 on Wednesday, March 19, 2025 at 7:00 am Eastern Daylight Time (EDT) / 11:00 am Greenwich Mean Time (GMT) / 7:00 pm Hong Kong Time (HKT). Analysts and investors are invited to join a conference call and audio webcast presentation with Q&A, conducted by HUTCHMED management. The English conference call and audio webcast will take place at 8:00 am EDT / 12:00 pm GMT / 8:00 pm HKT on Wednesday, March 19, 2025. In addition to the usual English webcast, there will also be a Chin

      2/19/25 3:30:00 AM ET
      $HCM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HUTCHMED Announces US$608 million Divestment of Non-Core Joint Venture

      — HUTCHMED continues to deliver on its strategy outlined in November 2022 to create value, prioritize its portfolio and bring innovative medicines to patients globally — — Divestment proceeds to advance HUTCHMED's pipeline and core innovative medicines business — — Focused R&D investment includes HUTCHMED's proprietary antibody-targeted therapy conjugate platform, with first candidates expected to enter clinical trials in the second half of 2025 — HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Jan. 01, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:HCM; HKEX:13) announces that it has entered into two agreements to divest its 45% equity interest in Shang

      1/1/25 5:46:43 AM ET
      $HCM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HUTCHMED to Announce 2024 Half-Year Financial Results

      HONG KONG and SHANGHAI and FLORHAM PARK, N.J., June 26, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM: HCM; SEHK:13) will be announcing its interim results for the six months ended June 30, 2024 on Wednesday, July 31, 2024 at 7:00 am Eastern Daylight Time (EDT) / 12:00 noon British Summer Time (BST) / 7:00 pm Hong Kong Time (HKT). Analysts and investors are invited to join a conference call and audio webcast presentation with Q&A, conducted by HUTCHMED management. The English conference call and audio webcast will be held on Wednesday, July 31, 2024, at 8:00 am EDT (1:00 pm BST / 8:00 pm HKT). The Chinese (Putonghua) webcast will be held at 8:30 am HKT /

      6/26/24 4:30:00 AM ET
      $HCM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HCM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by HUTCHMED (China) Limited (Amendment)

      SC 13G/A - HUTCHMED (China) Ltd (0001648257) (Subject)

      2/13/23 3:54:30 PM ET
      $HCM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by HUTCHMED (China) Limited (Amendment)

      SC 13G/A - HUTCHMED (China) Ltd (0001648257) (Subject)

      2/11/22 11:19:49 AM ET
      $HCM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by HUTCHMED (China) Limited (Amendment)

      SC 13D/A - HUTCHMED (China) Ltd (0001648257) (Filed by)

      2/7/22 6:12:18 AM ET
      $HCM
      Biotechnology: Pharmaceutical Preparations
      Health Care